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Influenza vaccination practice, which is based on neutralizing antibodies, requires being able to predict which viral
strains will be circulating. If an unexpected strain, as in the 1997 H5N1 Hong Kong outbreak, or even a pandemic
emerges, appropriate vaccines may take too long to prepare. Therefore, strategies based on conserved influenza
antigens should be explored. We studied DNA vaccination in mice with plasmids expressing conserved nucleopro-
tein (NP) and matrix (M) from an H1N1 virus. After vaccination, mice were challenged with A/H5N1 viruses of low,
intermediate, and high lethality. A/NP+A/M DNA vaccination reduced replication of A/Hong Kong/486/97 (HK/486),
a nonlethal H5N1 strain, and protected against lethal challenge with more virulent A/Hong Kong/156/97 (HK/156).
After HK/156 exposure, mice survived rechallenge with A/Hong Kong/483/97 (HK/483), although the DNA vaccina-
tion alone protected poorly against this highly virulent strain. In the absence of antigenically matched hemaggluti-
nin-based vaccines, DNA vaccination with conserved influenza genes may provide a useful first line of defense
against a rapidly spreading pandemic virus.
he 1997 outbreak of H5N1 avian influenza in humans in
Hong Kong (1,2) caused alarm because it involved highly
pathogenic strains of an influenza subtype to which humans
lack immunity. This outbreak led to fears about inability to
control a pandemic if a new strain should spread efficiently
from human to human. Although prevention by vaccination is
more desirable than treatment after infection, conventional
immunization strategies have major limitations. 
Neutralizing antibodies are specific to subtype and often
strain, so vaccination based on eliciting such antibodies
requires accurate prediction of the viral strains that will circu-
late during the influenza season and leaves little time for vac-
cine preparation. Even with usual epidemic strains, difficulties
and delays in the production of an adequate vaccine supply
have occurred in some years (3). A rapidly developing pan-
demic would shorten the timeframe to identify the viral strain
and prepare an antigenically matched vaccine, while the need to
vaccinate an entirely naïve population would exacerbate vac-
cine production and supply issues. In addition, H5 vaccine can-
didates, either H5 recombinant protein or a conventional
surface antigen vaccine prepared from apathogenic H5N3 virus,
have shown suboptimal immunogenicity in human trials (4,5).
A recent report on the molecular basis for virulence of
H5N1 viruses (6) was accompanied by an article that dis-
cussed related public health issues, in which Laver and Gar-
man (7) addressed the problem of how to control pandemics
and concluded that currently “the most promising first line of
defense” is use of antiviral drugs. These drugs, however,
reduce symptoms and duration of disease only partially (8),
and their effectiveness during H5N1 infection is unknown.
Laver and Garman further commented that various experimen-
tal vaccines, including DNA vaccines, may be more promising
for pandemic control. These statements highlight the fact that
additional approaches are needed to produce effective vac-
cines for H5N1 or other new subtypes (9).
Vaccines using conserved components of influenza A virus
can induce protection against many influenza A strains,
including those of divergent subtypes. Animal studies have
demonstrated potent and long-lasting heterosubtypic immu-
nity, that is, exposure to a virus of one subtype protects against
challenge infection with another subtype (10–15). The mecha-
nisms of heterosubtypic immunity are not completely under-
stood but likely include both T-cell immunity, in particular
CD8+ cytotoxic T-lymphocytes (CTL) (16,17) and CD4+ T
cells (13), as well as antibodies to conserved epitopes (18).
Heterosubtypic immunity has been reported in humans (19,
20), but its effectiveness and duration are unknown. Animal
studies may show ways to optimize induction of heterosub-
typic immunity, which could then be tested in humans. Hetero-
subtypic immunity induced by virus can protect against H5N1
infection in animals (21), and human T cells specific for anti-
gens of an H1N1 virus, including nucleoprotein (NP) and
matrix (M), can lyse target cells infected with H5N1 virus
(22). In addition, exposure to H9N2 virus can induce hetero-
subtypic protection against H5N1 challenge in chickens (23)
and mice (24).
 DNA vaccination can target immune responses to epitopes
that are highly conserved in influenza A viruses, while avoid-
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ing the risks of live-virus vaccines. We and others have previ-
ously shown that DNA constructs expressing conserved
influenza proteins induce antibody and T-cell responses and
protect against H3N2 heterosubtypic challenge (25–27). Both
CD4+ and CD8+ T cells play roles in this protective immunity.
DNA vaccination has also been studied in the H5N1 system,
although largely with constructs expressing HA. DNA con-
structs expressing H5 HA can protect against lethal H5N1
challenge in mice (28). In lethal challenge experiments with
chickens, an H5 HA construct protected fully and a construct
expressing NP of an H5N8 virus protected partially (29,30).
However, DNA vaccines expressing heterosubtypic antigens
have not been studied in the H5N1 system.
Studies of challenge with H5N1 viruses from the 1997
Hong Kong outbreak must take into account their phenotypic
diversity. While all these viruses were highly pathogenic in
chickens, two main pathogenicity phenotypes were observed
in mice (31,32). Viruses of the two types were studied for his-
topathology, viral titers in various tissues, and lethality in
mice. The  H3N2 viruses A/Udorn or X31 were used for com-
parison in some cases. Some isolates, represented by A/Hong
Kong/483/97 (HK/483), were lethal even at modest doses, rep-
licating in multiple organs, including the brain, liver, spleen,
and kidney after intranasal administration (31), resulting in
pathology of respiratory tissue and the heart, and producing
immune effects (33). Other isolates, represented by A/Hong
Kong/486/97 (HK/486), replicated only in the respiratory tract
and were not lethal. One virus, A/Hong Kong/156/97 (HK/
156), did not fit readily into either group, requiring higher
doses to infect or kill mice in one of the studies (31) and show-
ing some spread to nonrespiratory sites but more limited
spread than was seen with HK/483 (31,32). HK/483 and HK/
156, but not HK/486, were isolated from lethal infections in
the original human cases.
In this study, we extended DNA vaccination based on con-
served influenza components to heterosubtypic challenge with
H5N1 virus. We investigated whether the broadly cross-reac-
tive immunity induced by immunization of mice with DNA
expressing NP and M from a mouse-adapted human H1N1
virus, A/Puerto Rico/8/34 (A/PR/8), could control infection
with a range of H5N1 viruses.
Materials and Methods
Plasmid VR1012 was obtained from Vical Inc. (San Diego,
CA) under a Materials Transfer Agreement. Full-length influ-
enza genes for NP and M of A/PR/8 were prepared and
inserted into VR1012 as described previously (27). The plas-
mid B/NP expresses the full-length NP gene from B/Ann
Arbor/1/86 (B/AA), derived from a baculovirus vector gener-
ated by Rota et al. (34) and subcloned into VR1012. Plasmid
DNA was prepared and tested as described (27). Endotoxin
levels were <1 EU/100 µg dose.
H5N1 viruses used in this study were HK/156, HK/483,
HK/485, and HK/486 (31). Other viruses used were H1N1
virus A/PR/8; reassortant virus X-31 with surface glycopro-
teins of A/Aichi/2/68 (H3N2) and internal proteins of A/PR/8
virus; and B/AA. The A/PR/8 and X-31 stocks were mouse
adapted by passage through mouse lungs. Virus stocks were
propagated in the allantoic cavity of embryonated hen eggs at
37°C for 24 hr (H5N1 viruses) or 34°C for 48–72 hr (other
viruses). Fifty-percent egg infectious dose (EID50) titers and
mouse infectious dose (MID50) titers were determined by
serial titration in eggs or mouse lungs, respectively, and calcu-
lated by the method of Reed and Muench (35). All experi-
ments with infectious H5N1 viruses were conducted under
BSL-3+ containment, including work in animals. 
BALB/c female mice were purchased from the Division of
Cancer Treatment, National Cancer Institute, Frederick, Mary-
land, or from Jackson Laboratories, Bar Harbor, Maine. DNA
was injected intramuscularly, 100 µg/mouse of each plasmid,
three times at 2-week intervals, starting at 6–7 weeks of age.
Approximately 1 week after the last immunization, mice were
shipped from the Food and Drug Administration to Centers for
Disease Control and Prevention or U.S. Department of Agri-
culture, allowed to rest for approximately a week, challenged
under containment conditions with CO2 anesthesia, and moni-
tored for weight loss and death. For viral titers, lung and brain
tissues were collected 6 days postchallenge and frozen.
Enzyme-linked immunosorbent assay (ELISA) was per-
formed as described previously (15) on plates coated with
lysates of influenza virus–infected cells. Hemagglutination
inhibition (HI) was performed by standard methods with sera
pretreated with receptor-destroying enzyme (36).
Thawed tissues were homogenized in 1 mL of sterile phos-
phate-buffered saline. Clarified lung, brain, kidney, and nose
homogenates were titrated for virus infectivity in 10-day-old
embryonated eggs (EID50) from initial dilutions of 1:10 (lungs
and nose) or 1:2 (brain and kidney), with positive eggs identi-
fied by hemagglutination. Detection limits were 101.2 EID50/
mL for lung and nose, and 100.8 EID50/mL for brain and kid-
ney. Enzyme-linked immunospot assays (ELISPOT) for inter-
feron-γ  (IFN-γ ) secreting cells were performed as described
previously (37). 
For CTL assays, splenocytes were restimulated in vitro
and target cells prepared as described (38). CTL activity was
measured by lactate dehydrogenase (LDH) release (CytoTox
96 Non-Radioactive Cytotoxicity Assay kit G170, Promega
Corp., Madison, WI). Results were calculated as:
where target maximum represents target cells plus Promega
lysis solution containing detergent. Maximum cytotoxicity
occasionally exceeds 100% (Figure 1). The addition of targets
may alter spontaneous release from effectors, or detergent
lysis may differ from CTL-mediated lysis, but relative CTL
activity was consistent.
Results
Mice were immunized with a mixture of plasmids encod-
ing A/NP+A/M, intended to provide greater protection than aRESEARCH
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single antigen (27,39). Plasmid DNA without an insert is often
used as a control; although we used it initially, we later pre-
pared a construct expressing the NP gene of influenza B/AA as
a specificity control. The B/AA virus is only distantly related
antigenically to influenza A, and no cross-protection is seen
between influenza A and B viruses. The control plasmid
expressing B/NP protects against challenge with influenza B,
as shown by reduction in lung viral titers (40). 
A/NP+A/M DNA induced antibodies against homologous
A/PR/8 proteins (geometric mean ELISA titer 761), with no
cross-reactivity to influenza B proteins (all titers <20). Mice
immunized with B/NP DNA had comparable titers of antibody
to influenza B proteins, with no cross-reactivity to A/PR/8
proteins.
DNA immunization activated T cells in an antigen-specific
manner by two measures, ELISPOT of IFN-γ  secreting cells
and CTL activity. Splenocytes from mice immunized with A/
NP+A/M DNA generated an IFN-γ  ELISPOT response when
restimulated with NP147 peptide (the dominant CTL epitope in
BALB/c mice), A/PR/8 virus, or concanavalin A (Con A), but
not with control HA462 peptide, demonstrating antigen speci-
ficity (Figure 1a). Mice immunized with B/NP DNA did not
respond to restimulation with either peptide or with A/PR/8
but did respond to Con A, indicating the cells were functional. 
Antigen-specific CTL responses to DNA immunization
were seen after in vitro restimulation (Figure 1b). Cells from
mice immunized with A/NP+A/M DNA lysed A/PR/8-
infected targets if they had been restimulated with A/PR/8 but
not with B/AA. Controls immunized with B/NP DNA and
restimulated with B/AA generated cytolytic activity detectable
on influenza B-infected targets but not A/PR/8-infected tar-
gets.
A/NP+A/M DNA immunization was tested for protection
against an H5N1 challenge virus of low virulence, HK/486.
HK/486 is not lethal for mice, so control of virus replication
was measured. A/NP+A/M vaccination reduced replication of
HK/486 virus in the lungs approximately 17-fold, compared
with viral titers in mice vaccinated with control DNA or unim-
munized mice (Table, highly significant by Analysis of vari-
ance (ANOVA); see legend). As expected, infection of mice
with X-31 virus induced substantial heterosubtypic immunity,
reducing lung virus titers by approximately 3,000-fold com-
pared with unvaccinated controls. 
Next, we tested the ability of A/NP+A/M DNA vaccina-
tion to protect against HK/156, an H5N1 challenge virus of
intermediate virulence. Mice vaccinated with A/NP+A/M
DNA had only minor weight loss after challenge, while mice
vaccinated with control DNA lost weight dramatically (Figure
2a). Four of mice per group were euthanized at day 6 after
challenge to measure virus replication in lungs and brains. A/
NP+A/M DNA immunization reduced lung titers by over two
logs (approximately 500-fold, highly significant by ANOVA,
Figure 2b). As expected (21), immunization with A/PR/8 virus
also reduced lung titers substantially. Reductions in brain titers
Figure 1. DNA vaccination induces T-cell responses. a) Enzyme-linked
immuno spot (ELISPOT) assay for interferon-γ  (IFN-γ ) secreting cells.
Mice were immunized three times with A/NP+A/M or influenza B nucle-
oprotein DNA (B/NP DNA) intramuscularly. Spleen cells were analyzed
by ELISPOT, using peptides at 1 µg/mL or A/PR/8 live virus. Results
are the mean of three experiments. No response to A/PR/8 virus
occurred in one experiment. Concanavalin A (Con A) responses: A/
NP+A/M groups, >274 for all experiments; B/NP groups, >329 for all
experiments. b) Cytotoxic T-cell assay. Mice were vaccinated as above
or with live A/PR/8 virus given on the day of the second DNA injection.
Spleens were harvested 2½ weeks after the third DNA injection. Spleen
cells were restimulated in vitro with live A/PR/8 or B/AA. After 7 days of
culture, restimulated effector cells at various ratios were mixed with
P815 target cells infected with A/PR/8 or B/AA, and lactate dehydroge-
nase (LDH) release measured.Emerging Infectious Diseases  •  Vol. 8, No. 8, August 2002 799
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were not statistically significant because virus titers in the
brain were low even in B/NP DNA-immunized controls. 
Mice vaccinated (six per group) with A/NP+A/M DNA all
survived a HK/156 challenge dose lethal to controls, as did A/
PR/8-primed mice (Figure 2c). Thus, DNA vaccination with
conserved components is effective not only against strains of
low virulence like HK/486 but also against a lethal strain.
However, A/NP+A/M DNA vaccination was not protective
against challenge with 100 MID50 of highly virulent A/HK/
483 (none of six mice survived). An additional experiment
used 100 MID50 and a lower challenge dose of HK/483 to
determine whether A/NP+A/M DNA vaccination could pro-
tect against a less extreme challenge. Challenge with 100
MID50 of HK/483 again killed all the mice vaccinated with A/
NP+A/M DNA (0/8 survived). With a challenge dose of 10
MID50, four of eight mice vaccinated with A/NP+A/M DNA
survived, but zero of eight given B/NP DNA and zero of eight
naïve controls survived. These results suggest some protective
effect, though the numbers are not statistically significant. Pre-
liminary testing of viral titers in lung, nose, kidney, and brain
at day 6 showed significant differences in the lungs and noses
between A/NP+A/M immunized mice and controls, suggest-
ing some impact of the immunization (data not shown).
A/NP+A/M DNA-vaccinated mice that survived HK/156
infection (above) were rechallenged 14 weeks later with 100
MID50 of the virulent HK/483 strain. Since mice vaccinated
with control DNA had all died after HK/156 challenge, a
group of naïve animals was added to the HK/483 challenge to
confirm lethality of the challenge dose. All mice primed with
A/NP+A/M DNA and subsequently exposed to HK/156 sur-
vived this HK/483 challenge, whereas all naïve mice died by
day 8 (Figure 2d). 
Anti-HA (H5) antibodies induced by HK/156 exposure
might account for the protection against HK/483 infection. To
assess this possibility, we tested for HI reactivity in sera from
the mice after HK/156 exposure but before HK/483 challenge.
All mice immunized with A/NP+A/M DNA and then exposed
to HK/156 had antibodies reactive with HK/156 and cross-
reactive with HK/483 and HK/485 viruses in HI, while control
naïve mice had no detectable antibody (data not shown). 
Discussion
The most straightforward approach to vaccination against
a newly emerging influenza subtype is use of inactivated virus
or recombinant HA. However, if antigenically matched vac-
cines were not available in time or in sufficient quantity, other
options would be important. Our study examines one of these.
DNA vaccination using genes for conserved antigens
could have several advantages. The constructs could be avail-
able at any time. Plasmid production in bacteria is more con-
sistent than growth of different viruses in eggs, and a cold
chain might not be necessary for storage. To explore the use-
fulness of this approach, we studied the ability of NP+M DNA
vaccines derived from A/PR/8 (H1N1) to protect against
H5N1 challenge. 
Vaccination with A/NP+A/M DNA readily induced anti-
gen-specific antibody and T-cell responses, as shown previ-
ously (26,27). We investigated the potential for A/NP+A/M
DNA vaccination to control infection by H5N1 viruses of
modest (HK/486), intermediate (HK/156), and very high (HK/
483) virulence phenotypes. Upon challenge with HK/486, a
Table. Effect of DNA vaccination on replication of HK/486 challenge 
virus in mouse lungsa 
Immunization No. mice Lung titer +/- SE 
Expt 1A
A/NP+A/M DNA 6 5.7 ± 0.33
B/NP + blank DNA 6 6.9 ± 0.18b
None 6 6.9 ± 0.22c
Expt 1B
Live X-31 virus 4 3.6 ± 0.36d
None 4 7.1 ± 0.1
aMice were immunized intramuscularly with 100 µg each of influenza A nucleoprotein 
and matrix DNA (A/NP+A/M DNA) or controls with 100 µg each of influenza B nucle-
oprotein DNA (B/NP)+blank DNA (total dose 200 µg/mouse on each occasion), three 
times at 2-week intervals.  Two weeks after the last dose of DNA, mice were challenged 
with 100 mouse infectious dose (MID)50 of HK/486 intranasally. X31 virus-primed 
mice and their controls were challenged along with DNA-vaccinated mice. On day 6 
after challenge, mice were sacrificed and lungs collected for titration of virus infectivity.
bDiffers significantly from A/NP+A/M group by analysis of variation (ANOVA), 
p=0.0082.
cDiffers significantly from A/NP+A/M group by ANOVA, p=0.011.
dDiffers significantly from unimmunized group by ANOVA, p<0.001.
Figure 2. Mice immunized with influenza A nucleoprotein and matrix
DNA (A/NP+A/M DNA) are protected against lethal A/Hong Kong/156/
97 (HK/156) challenge. Mice were vaccinated as in Figure 1 with A/
NP+A/M DNA, with influenza B nucleoprotein DNA (B/NP+blank DNA),
or with 100 mouse infectious dose (MID)50   of  influenza A/Puerto
Rico8/34 (A/PR/8) live virus. Sixteen days after the last dose of DNA,
mice were challenged with 10,000 MID50 of HK/156/97 intranasally. a)
Monitoring of morbidity by body weight loss. b) Viral titers of lung and
brain homogenates. Each bar represents the result for one mouse.
Dashed lines indicate detection limits. Compared to the B/NP DNA con-
trols, lung titers were significantly reduced in the A/NP+A/M DNA group
(p=0.001, analysis of variation (ANOVA)) and the A/PR/8 group
(p<0.001, ANOVA). c) Survival after challenge with HK/156.  d) Survival
after rechallenge with 100 MID50 of HK/483 of mice primed with A/
NP+A/M DNA and which had all survived the previous HK/156 infection. RESEARCH
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strain that is not lethal in mice, lung titers were reduced
approximately 17-fold. In previous work, even a 5- to 10-fold
reduction in peak lung virus titers correlated with immunity
protective against lethal challenge (14), so a 17-fold reduction
and the accompanying difference in kinetics of viral clearance
could alter biologic outcomes. In a test of its effectiveness, the
vaccination provided benefit in the case of lethal challenge
with HK/156, resulting in 100% survival and minimal morbid-
ity as measured by weight loss, while unvaccinated controls
demonstrated large weight losses and 100% death rates. After
surviving HK/156 infection, the mice were resistant to lethal
HK/483 challenge. Antibodies to HK/156 were demonstrated
by HI to be present and cross-reactive with HK/483 virus
before HK/483 challenge, which might account for the protec-
tion against HK/483. Of mice vaccinated only with A/NP+A/
M DNA, half survived challenge with a dose of HK/483 lethal
to all controls. While not statistically significant, the trend sug-
gests some impact from immunization. 
Regarding immune mechanisms of protection by A/NP+A/
M DNA vaccination, candidates include CTL specific for NP
(17) and antibodies to the N-terminal portion of M2 (18). Con-
taining an infection with the kinetics of HK/483 may be diffi-
cult because it reaches near peak titers in as little as 24 hours.
Only neutralizing antibody may be effective that early. Anti-
gen presentation and reactivation of T-cell effectors take sev-
eral days. However, when T cells specific for viral antigens are
expanded substantially, they can reduce replication of highly
lethal influenza viruses and clear infection more rapidly (41).
Comparing amino acid sequences in GenBank from
viruses of five subtypes, NPs were >90% identical, with con-
siderable conservation of known dominant CTL epitopes. M1
sequences were >94% conserved, while M2 sequences varied
somewhat more. However, not all protective epitopes are
known, and even single mutations can alter protective
epitopes. Therefore, studies like the present one are necessary
for establishing the range of virus strains against which a vac-
cine can work.
H5 viruses differ in virulence, and one cannot predict
which strain might emerge in a future pandemic. With the
threat of a pandemic and suboptimal existing vaccine candi-
dates, new approaches to influenza vaccination should be con-
sidered. Our results suggest that DNA vaccination with
conserved components has the potential to ameliorate disease
caused by H5N1 viruses. The immunity induced by this mode
of DNA vaccination does not completely prevent infection but
passed the stringent test of protecting against lethal H5N1
challenge. Vaccines inducing neutralizing antibody could be
administered subsequently to confer immunity against even
the most virulent strains. In the absence of an antigenically
matched HA-based vaccine, this approach might be useful as a
first line of defense against a rapidly spreading influenza pan-
demic and should be further explored.
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